Literature DB >> 22608884

Altered frequency of T regulatory cells is associated with disability status in relapsing-remitting multiple sclerosis patients.

Lasse Bjerg1, Anne Brosbøl-Ravnborg, Caroline Tørring, Anders Dige, Bettina Bundgaard, Thor Petersen, Per Höllsberg.   

Abstract

A perturbed immunoregulation may be part of the pathogenesis of relapsing-remitting multiple sclerosis (RRMS). In this study, we demonstrate a dichotomy within the frequency of Treg among newly diagnosed RRMS patients but not in healthy controls. A group of RRMS patients was characterized by a significantly lower percentage of Treg cells than that of their matched, healthy controls, and this was inversely correlated with their score on the expanded disability status scale (EDSS). Since the EDSS reflected severity of the last attack, this study demonstrates a correlation between low frequency of Treg and severity of clinical disease in RRMS.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22608884     DOI: 10.1016/j.jneuroim.2012.04.012

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  15 in total

1.  Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.

Authors:  Evis Havari; Michael J Turner; Juanita Campos-Rivera; Srinivas Shankara; Tri-Hung Nguyen; Bruce Roberts; William Siders; Johanne M Kaplan
Journal:  Immunology       Date:  2014-01       Impact factor: 7.397

2.  Induction of regulatory T-cells from memory T-cells is perturbed during acute exacerbation of multiple sclerosis.

Authors:  Imran H Mohiuddin; Vinodh Pillai; Ethan J Baughman; Benjamin M Greenberg; Elliot M Frohman; Michael P Crawford; Sushmita Sinha; Nitin J Karandikar
Journal:  Clin Immunol       Date:  2016-05-03       Impact factor: 3.969

Review 3.  Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.

Authors:  Samantha Messina
Journal:  Small GTPases       Date:  2018-09-18

4.  The role of IL-2 in the activation and expansion of regulatory T-cells and the development of experimental autoimmune encephalomyelitis.

Authors:  Michael Rouse; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Immunobiology       Date:  2012-08-09       Impact factor: 3.144

5.  Multiple sclerosis patients have reduced resting and increased activated CD4+CD25+FOXP3+T regulatory cells.

Authors:  Nirupama D Verma; Andrew D Lam; Christopher Chiu; Giang T Tran; Bruce M Hall; Suzanne J Hodgkinson
Journal:  Sci Rep       Date:  2021-05-18       Impact factor: 4.379

Review 6.  The effects of twenty-four nutrients and phytonutrients on immune system function and inflammation: A narrative review.

Authors:  Jillian Poles; Elisa Karhu; Megan McGill; H Reginald McDaniel; John E Lewis
Journal:  J Clin Transl Res       Date:  2021-05-27

7.  Adipocytokine profile, cytokine levels and foxp3 expression in multiple sclerosis: a possible link to susceptibility and clinical course of disease.

Authors:  Solaleh Emamgholipour; Seyede Mahdieh Eshaghi; Arash Hossein-nezhad; Khadijeh Mirzaei; Zhila Maghbooli; Mohammad Ali Sahraian
Journal:  PLoS One       Date:  2013-10-03       Impact factor: 3.240

Review 8.  Teriflunomide and its mechanism of action in multiple sclerosis.

Authors:  Amit Bar-Or; Andrew Pachner; Francoise Menguy-Vacheron; Johanne Kaplan; Heinz Wiendl
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

9.  Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens.

Authors:  Maria Rodi; Nikolaos Dimisianos; Anne-Lise de Lastic; Panagiota Sakellaraki; George Deraos; John Matsoukas; Panagiotis Papathanasopoulos; Athanasia Mouzaki
Journal:  Int J Mol Sci       Date:  2016-08-25       Impact factor: 5.923

10.  Extracellular vesicles from human umbilical cord blood plasma modulate interleukin-2 signaling of T cells to ameliorate experimental autoimmune encephalomyelitis.

Authors:  Sueon Kim; Ji-Young Maeng; Seung-Joo Hyun; Hyun-Jung Sohn; Su-Yeon Kim; Cheol-Hwa Hong; Tai-Gyu Kim
Journal:  Theranostics       Date:  2020-04-06       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.